Why did Fortrea (FTRE) stock move recently?

On 8/4/2026, Fortrea moved -5.0% — Fortrea shares declined following an Aug 3 announcement of an insider's planned Rule 144 sale of 9,700 shares, with the drop continuing from the prior session after the company's July 29 earnings release that included raised full-year guidance. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Fortrea (FTRE) overvalued or fairly valued?

MarketChacha shows Fortrea's valuation in context — a forward P/E of about 15.9, a price-to-book of about 3.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Fortrea's revenue?

Fortrea reported revenue of $2.7B for FY2025, with net profit of $-986.2M, per official filings.

What is the share price of Fortrea (FTRE)?

Fortrea last traded at $17.60 (-2.8% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Fortrea

FTRE · NYSE · Healthcare · United States

Snapshot

TickerFTRE

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees14,000

HeadquartersDurham, United States

Websitewww.fortrea.com

Filings tracked16

About Fortrea

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Who owns it

Insiders1.2%
Institutions98.8%
Public & other0.0%

445 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.61%
Goldman Sachs Group Inc8.85%
Sessa Capital IM, L.P.4.83%
Vanguard Capital Management LLC4.40%
Vanguard Portfolio Management LLC4.01%
State Street Corporation3.98%
FMR, LLC3.83%
Corvex Management LP3.14%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 35.3 points over the period — profitability is trending down.

Net margin trend-0.9% → -36.2%

Margin has compressed by about 35.3 points over the period — profitability is trending down.

Return on equity-175.0%

Latest ROE of -175.0% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $676.6M · EPS 0.24

Est. earnings growth +167.3%

Next fiscal year

Rev $2.7B · EPS 1.14

Est. earnings growth +35.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.7B

Net margin

-36.2%

ROE

-175.0%

Revenue CAGR (2y)

-2.1%

EPS (FY2025)

-10.81

Net profit (FY2025)

$-986.2M

Ask MarketChacha about FTRE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Fortrea shares declined following an Aug 3 announcement of an insider's planned Rule 144 sale of 9,700 shares, with the drop continuing from the prior session after the company's July 29 earnings release that included raised full-year guidance.
source 1 ↗source 2 ↗· confidence: medium
Jul 23, 2026
No specific company catalyst identified for the gain; the stock rose ahead of its scheduled Q2 earnings release on July 29 with no new filings or announcements today.
· confidence: low
Jul 22, 2026
No specific company catalyst or news event identified for the gain; FTRE moved with the broader market or sector amid upcoming Q2 earnings scheduled for July 29.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about FTRE

Why is IQVIA up ~12% today — the S&P 500's top gainer?c/usmarkets · 7/28/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.7B	$-986.2M	-10.81	-36.2%	-175.0%
FY2024	$2.7B	$-328.5M	-3.67	-12.2%	-24.1%
FY2023	$2.8B	$-25.2M	-0.29	-0.9%	-1.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$678.2M	$-13.2M	-0.14	-1.9%
2026Q1	$636.5M	$-23.6M	-0.25	-3.7%
2025Q3	$701.3M	$-15.9M	-0.17	-2.3%
2025Q2	$710.3M	$-374.9M	-4.14	-52.8%
2025Q1	$651.3M	$-562.9M	-6.25	-86.4%
2024Q3	$674.9M	$-27.9M	-0.31	-4.1%
2024Q2	$662.4M	$-138.4M	-1.55	-20.9%
2024Q1	$662.1M	$-101.0M	-1.13	-15.3%
2023Q3	$713.8M	$-14.0M	-0.16	-2.0%
2023Q2	$725.1M	$30.8M	0.35	4.2%
2023Q1	$693.9M	$12.5M	0.14	1.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/29/2026
8-K — Results of operations, Executive/director change, Exhibits
SEC7/29/2026material
8-K — Executive/director change
SEC7/14/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/26/2026material
8-K — Shareholder vote results
SEC6/12/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026

2025

8-K — Reg FD disclosure
SEC11/20/2025material
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/22/2025material
8-K — Executive/director change
SEC8/27/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.